ablack

Donya Moslemzadeh

PhD Student

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Social: linkedin logo

 

 

 

 

 

 

 
Background

Donya obtained her Doctor of Pharmacy (Pharm.D.) degree in 2016 from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After completing her studies, she worked in a biopharmaceutical company for several years, taking various roles from marketing and branding to executive positions. After moving to the Netherlands, she followed a Master’s in Epidemiology at Utrecht University, specializing in pharmacoepidemiology, and graduated in 2024. Her master’s research focused on developing methods to detect adverse drug reactions earlier than conventional methods using real-world data and pharmacoepidemiologic methodologies.

Currently, Donya is pursuing a PhD at the department of Medical Informatics in collaboration with the Dutch Medicine Evaluation Board (CBG-MEB) focusing on the role of real-world evidence on regulatory decision making for medicines.

Publications

  • Pourheidar, Elham, Rezvan Hassanpour, Donya Moslemzadeh, Majid Mokhtari, Mehran Kouchek, Mir Mohammad Miri, Mehrdad Haghighi, and Mohammad Sistanizad. 2021. “The Effect of The Number of Potential Drug-Drug Interactions and Prescribed Medications on Length of Stay and Mortality Rate of Patients in The Intensive Care Unit: Drug-Drug Interactions and ICU Outcome”. International Pharmacy Acta 4 (1), 4e7:1-4. https://doi.org/10.22037/ipa.v4i1.34106.

Oral Presentation

2024: Donya Moslemzadeh, Patrick C. Souverein, Svetlana Belitser, Eibert R. Heerdink, Olaf H. Klungel, Shahab Abtahi.  Early identification of the association between rofecoxib and cardiovascular adverse events using real-world data from the UK: A case-control and case-crossover design. WEON 2024, Utrecht, Netherlands.  (won the student award)
https://weon.nl/programme/parallel-sessions/

Poster presentation

2024: Donya Moslemzadeh, Patrick C. Souverein, Svetlana Belitser, Eibert R. Heerdink, Olaf H. Klungel, Shahab Abtahi.  Early identification of the association between rofecoxib and cardiovascular adverse events using real-world data from the UK: A case-control and case-crossover design. ISPE 2024, Berlin, Germany. https://2024ispe.eventscribe.net/posterspeakers.asp?pfp=BrowsebySpeaker